PMID- 25194974
OWN - NLM
STAT- MEDLINE
DCOM- 20160301
LR  - 20150608
IS  - 1578-8989 (Electronic)
IS  - 0025-7753 (Linking)
VI  - 144
IP  - 12
DP  - 2015 Jun 22
TI  - [New therapies for type 2 diabetes mellitus].
PG  - 560-5
LID - S0025-7753(14)00264-4 [pii]
LID - 10.1016/j.medcli.2014.03.018 [doi]
AB  - The increasing prevalence of obesity and type 2 diabetes mellitus (T2DM) has led 
      to a growing interest in the investigation of new therapies. Treatment of T2DM 
      has focused on the insulinopenia and insulin resistance. However, in the last 10 
      years, new lines of research have emerged for the treatment of T2DM and 
      preclinical studies appear promising. The possibility of using these drugs in 
      combination with other currently available drugs will enhance the antidiabetic 
      effect and promote weight loss with fewer side effects. The data provided by 
      post-marketing monitoring will help us to better understand their safety profile 
      and potential long-term effects on target organs, especially the cardiovascular 
      risk.
CI  - Copyright (c) 2014 Elsevier Espana, S.L.U. All rights reserved.
FAU - Puig-Domingo, Manuel
AU  - Puig-Domingo M
AD  - Servicio de Endocrinologia y Nutricion, Hospital Universitari i Institut 
      d'Investigacio en Ciencies de la Salut Germans Trias i Pujol, Universitat 
      Autonoma de Barcelona, Campus de Can Ruti, Badalona, Barcelona, Espana. 
      Electronic address: mpuigd@gmail.com.
FAU - Pellitero, Silvia
AU  - Pellitero S
AD  - Servicio de Endocrinologia y Nutricion, Hospital Universitari i Institut 
      d'Investigacio en Ciencies de la Salut Germans Trias i Pujol, Universitat 
      Autonoma de Barcelona, Campus de Can Ruti, Badalona, Barcelona, Espana.
LA  - spa
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Nuevos agentes terapeuticos para la diabetes tipo 2.
DEP - 20140904
PL  - Spain
TA  - Med Clin (Barc)
JT  - Medicina clinica
JID - 0376377
RN  - 0 (Anti-Obesity Agents)
RN  - 0 (Drugs, Investigational)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (GLP1R protein, human)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Incretins)
RN  - 0 (Insulin, Long-Acting)
RN  - 0 (Sodium-Glucose Transport Proteins)
RN  - 9007-92-5 (Glucagon)
RN  - EC 1.1.1.146 (11-beta-Hydroxysteroid Dehydrogenase Type 1)
RN  - EC 1.1.1.146 (HSD11B1 protein, human)
RN  - EC 2.3.1.20 (Diacylglycerol O-Acyltransferase)
RN  - EC 2.7.1.105 (Phosphofructokinase-2)
RN  - EC 2.7.1.2 (Glucokinase)
RN  - EC 3.4.14.5 (DPP4 protein, human)
RN  - EC 3.4.14.5 (Dipeptidyl Peptidase 4)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - 11-beta-Hydroxysteroid Dehydrogenase Type 1/antagonists & inhibitors
MH  - Anti-Obesity Agents/adverse effects/therapeutic use
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy
MH  - Diacylglycerol O-Acyltransferase/antagonists & inhibitors
MH  - Dipeptidyl Peptidase 4/drug effects
MH  - Drug Therapy, Combination
MH  - Drugs, Investigational/adverse effects/therapeutic use
MH  - Enzyme Inhibitors/therapeutic use
MH  - Glucagon/agonists
MH  - Glucagon-Like Peptide-1 Receptor/agonists
MH  - Glucokinase/drug effects
MH  - Gluconeogenesis/drug effects
MH  - Glucose/pharmacokinetics
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/classification/pharmacology/*therapeutic use
MH  - Incretins
MH  - Insulin Resistance
MH  - Insulin, Long-Acting/therapeutic use
MH  - *Molecular Targeted Therapy
MH  - Obesity/complications/drug therapy
MH  - Phosphofructokinase-2/antagonists & inhibitors
MH  - Sodium-Glucose Transport Proteins/antagonists & inhibitors
MH  - Weight Loss
OTO - NOTNLM
OT  - Diabetes tipo 2
OT  - Future
OT  - Futuro
OT  - Tratamiento
OT  - Treatment
OT  - Type 2 diabetes mellitus
EDAT- 2014/09/10 06:00
MHDA- 2016/03/02 06:00
CRDT- 2014/09/08 06:00
PHST- 2014/03/04 00:00 [received]
PHST- 2014/03/13 00:00 [accepted]
PHST- 2014/09/08 06:00 [entrez]
PHST- 2014/09/10 06:00 [pubmed]
PHST- 2016/03/02 06:00 [medline]
AID - S0025-7753(14)00264-4 [pii]
AID - 10.1016/j.medcli.2014.03.018 [doi]
PST - ppublish
SO  - Med Clin (Barc). 2015 Jun 22;144(12):560-5. doi: 10.1016/j.medcli.2014.03.018. 
      Epub 2014 Sep 4.